106147-85-7

Usage

Uses

Used in Synthetic Chemistry:
4-(Chloromethyl)-5-methyl-1-(triphenylmethyl)-1H-imidazole is used as a reagent in synthetic chemistry for [application reason]. Its unique structure and properties make it a valuable component in the synthesis of various organic compounds and pharmaceuticals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(Chloromethyl)-5-methyl-1-(triphenylmethyl)-1H-imidazole is used as a key intermediate in the synthesis of [specific drug or class of drugs] for [application reason]. Its presence in the molecular structure can contribute to the drug's efficacy, stability, or other desired properties.
Used in Research and Development:
4-(Chloromethyl)-5-methyl-1-(triphenylmethyl)-1H-imidazole is also used in research and development as a model compound to study the properties and reactions of tritylimidazoles. This can help scientists better understand the behavior of similar compounds and develop new synthetic routes or applications.

Upstream product

• 29636-87-1 4⁽⁵⁾-methyl-5⁽⁴⁾-hydroxymethylimidazole 
• 76-83-5 trityl chloride 
• 106147-84-6 4-Hydroxymethyl-5-methyl-1-(triphenylmethyl)imidazole 

Downstream Products

• 143075-63-2 2-(5-Methyl-1-trityl-1H-imidazol-4-ylmethyl)-5-nitro-2H-isoquinolin-1-one 
• 143075-60-9 2-(5-Methyl-1-trityl-1H-imidazol-4-ylmethyl)-2H-benzo[c][2,6]naphthyridin-1-one 

Relevant academic research and scientific papers

Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I

A series of compounds based on the carboxyl-terminal CAAL sequence of PGGTase-I substrates was designed and synthesized. Using piperazin-2-one as a semi-rigid scaffold, we have introduced critical pharmacophores in a well-defined arrangement to mimic the CAAL sequence. High potency and exceptional selectivity were obtained for inhibition of PGGTase-I with structures such as 45 and 70. Potency of this series of GGTIs was dependent on the presence of an l-leucine residue with a free carboxyl terminus, as well as an S configuration of the 3-aryl group. The selectivity was significantly enhanced by 5-methyl substitution on the imidazole ring and fluorine substitution on the 3-aryl group. Modification of the 6-position of the piperazinone scaffold was found to be unfavorable. Compounds 44 and 69, the corresponding methyl esters of 45 and 70, were found to selectively block processing of Rap1A by PGGTase-I in whole cells with IC50 values of 0.4 M and 0.7 M respectively. The Royal Society of Chemistry 2006.

SSR182289A, a selective and potent orally active thrombin inhibitor

SSR182289A 1 is the result of a rational optimisation process leading to an orally active thrombin inhibitor. The structure incorporates an original 2-(acetylamino)-[1,1′-biphenyl]-3-sulfonyl N-terminal motif, a central L-Arg surrogate carrying a weakly basic 3-amino-pyridine, and an unusual 4-difluoropiperidine at the C-terminus. Its synthesis is convergent and palladium catalysis has been employed for the construction of the key C-C bonds: Suzuki coupling for the bis-aryl fragment and Sonogashira reaction for the δ-ε bond of the central amino-acid chain. The compound is a potent inhibitor of thrombin's activities in vitro and demonstrates potent oral anti-thrombotic potencies in three rat models of thrombosis. The observed in vitro potency could be rationalized through the examination of the interactions within the SSR182289A 1 - thrombin crystal structure. SSR182289A 1, has been therefore selected for further development.

3,3-disubstituted-oxindole derivatives useful as anticancer agents

The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein n is 0 or 1 and R1, R2, R3, R4, and R5are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment, and to methods of preparing compounds of formula 1.

Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new α2-adrenoreceptor antagonists

4(5)-(2,2-diphenylethyl)imidazole 6a is described as being a potent (pK(i) = 8.16 for displacement of [3H] p-aminoclonidine) and selective (selectivity = -log (pK(i) α2 - pK(i) α1) = 81) α2-adrenoreceptor antagonist (pA2 = 8.73 versus clonidine in the electrically stimulated guinea pig ileum) with additional activity as a norepinephrine uptake inhibitor (IC50 = 0.3 μM). An investigation of the structure-activity relationships of compounds closely related to 6a has been carried out. This included substitution of the phenyl and imidazole rings and modification of the link between these two ring systems. The various synthetic routes used are described. The affinity and the selectivity of the compounds for the α2 site were determined by studying the displacement of [3H] p-aminoclonidine and [3H] WB-4101 from rat forebrain membranes. The efficacy of the compounds was defined by measuring the antagonism of the clonidine effect on the electrically stimulated guinea pig ileum.

ALPHA2-BLOCKING DERIVATIVES OF IMIDAZOLE

A compound of the formula: STR1 wherein X 1, X 2, Y 1 and Y 2, whether or not identical are hydrogen, a halogen such as fluoro, chloro or bromo, linear or branched alkyl of 1 to 3 carbon atoms, linear or branched alkoxy of 1 to 3 carbon atoms, carboxy, alkoxy-carbonyl of 1 to 3 carbon atoms or phenyl;R 1 is hydrogen, methyl or phenyl;R 2 and R 3, which may or may not be identical, are hydrogen, hydroxyl, linear or branched alkyl of 1 to 6 carbon atoms, or linear or branched alkoxy group of 1 to 4 carbon atoms;R 1 and R 2 may together form a carbon-carbon double bond; andR 4 and R 5 whether or not identical, are hydrogen, linear or branched alkyl or 1 to 3 carbon atoms.The compounds are useful as blocking agents of α 2-adrenergic receptors.